Tissue Regenix Group PLC Appointment of CEO (3338V)
November 02 2017 - 3:00AM
UK Regulatory
TIDMTRX
RNS Number : 3338V
Tissue Regenix Group PLC
02 November 2017
Tissue Regenix Group plc
Appointment of CEO
Steve Couldwell appointed Group CEO
Leeds, 02 November 2017 - Tissue Regenix Group (AIM:TRX)
("Tissue Regenix" or "The Group") the regenerative medical devices
company announces the appointment of Steve Couldwell, as Chief
Executive Officer of the Group, effective immediately. Steve has
been in the position of non- executive director since July
2013.
Steve has over 25 years' experience in the pharmaceutical and
medical device industry and a proven track record of delivering
revenue and profit growth. Most recently Steve was Chief Operating
Officer - Global Sanofi Biosurgery, with responsibility for
strategy and execution for global business including manufacturing,
regulatory, medical affairs and marketing/ commercial execution,
delivering strong double digit growth internationally for 3
consecutive years. Prior to this Steve held a number of roles at
Smith & Nephew including President, Orthopaedics, Europe and
Senior VP Sales and Marketing of the Advanced Wound Management
business.
Steve Couldwell, Tissue Regenix incoming CEO commented: "Since
being appointed to the board in 2013 I have been impressed with the
great commercial potential of our dCELL platform. The recent
acquisition of CellRight Technologies has increased the market
potential and provided a highly complementary product range in the
$1.7bn[1] US bone graft and substitute market. I am delighted to be
appointed CEO and look
forward to leading the Group through the integration of
CellRight and expansion of commercial activities as we execute our
commercial strategy and grow our market share throughout the US and
the rest of the world."
John Samuel, Chairman, Tissue Regenix: "The Board and I are
delighted to welcome Steve as the Group's new CEO. He has an
exceptional track record of growing businesses and the Board firmly
believes that Steve has the required skillset and experience to
guide the Group along the pathway to profitability. Alongside this,
Steve has an in-depth knowledge of the Group thanks to his years as
a non-executive director making him an ideal candidate for this
position."
Additional information on Mr Couldwell
The following additional information is provided in accordance
with paragraph (g) of Schedule Two to the AIM Rules for
Companies:
Current and past Directorships and Partnerships for Steve
Couldwell within the last 5 years, aged 57:
Current
-- Tissue Regenix Group plc
-- Zilico
There is no further information required to be disclosed
pursuant to Schedule 2(g) of the AIM Rules.
For more Information:
Tissue Regenix Group plc Tel: 0330
Caitlin Pearson Head of Communications 430 3073
---------------------------------------- ---------------
Jefferies International Ltd Tel: 020
Simon Hardy / Christopher Binks 7029 8000
------------------------------------------ -------------
FTI Consulting Tel: 0203
Brett Pollard / Mo Noonan 727 1000
========================================== =============
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL(R) ') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
January 2016 saw the establishment of joint venture GBM-V, a multi-
tissue bank based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies(R)
, a biotech company that specializes in regenerative medicine and
is dedicated to the development of innovative osteoinductive and
wound care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
[1]
http://www.beckersspine.com/orthopedic-a-spine-device-a-implant-news/item/35889-medtronic-depuy-synthes-stryker-lead-north-american-bone-grafts-substitutes-market-7-observations.html
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAUGGAAGUPMPPG
(END) Dow Jones Newswires
November 02, 2017 03:00 ET (07:00 GMT)
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Sep 2023 to Sep 2024